Low BACH2 Expression Predicts Adverse Outcome in Chronic Lymphocytic Leukaemia

Abstract

Chronic lymphocytic leukaemia (CLL) is a heterogeneous disease with a highly variable clinical outcome. There are well-established CLL prognostic biomarkers that have transformed treatment and improved the understanding of CLL biology. Here, we have studied the clinical significance of two crucial B cell regulators, BACH2 (BTB and CNC homology 1, basic leucine zipper transcription factor 2) and BCL6 (B-cell CLL/lymphoma 6), in a cohort of 102 CLL patients and determined the protein interaction networks that they participate in using MEC-1 CLL cells. We observed that CLL patients expressing low levels of BCL6 and BACH2 RNA had significantly shorter overall survival (OS) than high BCL6- and BACH2-expressing cases. Notably, their low expression specifically decreased the OS of immunoglobulin heavy chain variable region-mutated (IGHV-M) CLL patients, as well as those with 11q and 13q deletions. Similar to the RNA data, a low BACH2 protein expression was associated with a significantly shorter OS than a high expression. There was no direct interaction observed between BACH2 and BCL6 in MEC-1 CLL cells, but they shared protein networks that included fifty different proteins. Interestingly, a prognostic index (PI) model that we generated, using integrative risk score values of BACH2 RNA expression, age, and 17p deletion status, predicted patient outcomes in our cohort. Taken together, these data have shown for the first time a possible prognostic role for BACH2 in CLL and have revealed protein interaction networks shared by BCL6 and BACH2, indicating a significant role for BACH2 and BCL6 in key cellular processes, including ubiquitination mediated B-cell receptor functions, nucleic acid metabolism, protein degradation, and homeostasis in CLL biology.

Whole-genome sequencing of chronic lymphocytic leukemia identifies subgroups with distinct biological and clinical features

“…6a ). A recent study showed that decreased BACH2 expression in CLL is associated with adverse outcomes 37 . Notably, the mutations we detected in this promoter were mostly clonal (median CCF = 0.99).…”

Exploring the prognostic necroptosis-related genes and underlying mechanism in sepsis using bioinformatics

“…It was revealed in our study that LEF1 might be downregulated and functionally associated with MLKL in sepsis. BACH2 is a key factor in B cell regulation, and low expression of BACHA2 can predict poor outcomes in chronic lymphocytic leukemia [7] It has been demonstrated that increased expression of BCL-2 contributes to tumor expansion, and impairment of BCL-2, considered an oncogene, has been implicated in the development of a wide range of cancerous manifestations, including lymphomas [11]. In the eld of sepsis, BCL2 is closely associated with multiple diseases caused by sepsis.…”

Prognostic and chemotherapeutic response prediction by proliferation essential gene signature: Investigating POLE2 in bladder cancer progression and cisplatin resistance

“…We identified BLCA-dependent genes based on the CERES score from the Depmap database. Essential genes were defined as genes with CERES scores <-1 in more than 75% of BLCA cell lines [25].…”